Gkasiamis, Argyrios
Mayo Clinic
Late Clinical Development, Hematology/Oncology and Cell Therapy, Bristol Myers Squibb, Boudry, Switzerland
Citations 11
THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)
Nowakowski, G. S., Kesanakurthy, V., Gkasiamis, Argyrios, Patah, Poliana, Delarue, Richard, Wang, T., Xian, Dehai , Martin, Peter , Morschhauser, Franck , Cartron, Guillaume , Li, J., Xian, D., Fox, Christopher P.
Hematological Oncology | June 17, 2021 | Volume: 39 | Issue: S2 | Pages: No page available
